Clodronate prevents immobilization osteopenia in rats

Area of Science:

• Orthopedics
• Pharmacology
• Bone Biology

Background:

• Immobilization osteopenia (IO) is a significant complication following nerve injury or surgery.
• Sciatic neurectomy in rats is a common model to induce IO.
• Understanding therapeutic interventions for IO is crucial for patient recovery.

Purpose of the Study:

• To evaluate the efficacy of clodronate in preventing or treating immobilization osteopenia.
• To determine the dose-dependent effect of clodronate on bone parameters in an IO model.
• To assess clodronate's impact on bone mineral density, ash weight, and mineral content.

Main Methods:

• Induction of IO in Wistar female rats via sciatic neurectomy.
• Administration of varying doses of clodronate (3, 10, 30 mg/kg/day) or saline control.
• Analysis of bone mineral density, ash weight, calcium, phosphorus, and magnesium content in tibiae after 7 weeks.

Main Results:

• Sciatic neurectomy led to a significant decrease in tibial ash weight (6.6%) and bone mineral density (5.1%).
• Clodronate administration dose-dependently attenuated these effects, with the highest dose fully neutralizing neurectomy-induced bone loss.
• Clodronate treatment restored the reduced calcium content in the bone ash to sham-operated levels, while the Ca/P ratio remained normal.

Conclusions:

• Clodronate is a promising therapeutic agent for preventing immobilization osteopenia.
• The protective effect of clodronate on bone is dose-dependent.
• Clodronate effectively preserves bone mineral density and calcium content in the context of nerve injury-induced osteopenia.